Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN MACROCRYSTALLINE versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN MACROCRYSTALLINE versus SATRIC.
NITROFURANTOIN MACROCRYSTALLINE vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit multiple bacterial enzymes involved in carbohydrate metabolism, including acetyl-CoA synthetase, and disrupt cell wall synthesis.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 100 mg orally every 12 hours for 10-14 days (pyelonephritis: not first-line).
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal half-life: 20-60 minutes (short, requires q6h dosing for therapeutic efficacy).
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Renal: 30-40% excreted unchanged in urine. Biliary/fecal: minimal; remainder metabolized or eliminated via other routes.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category D/X
Category C
Antibiotic
Antiprotozoal, Antibiotic